Reata Pharma (RETA) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
August 9, 2021 4:01 PM EDTPRE-NDA MEETING WITH FDA SCHEDULED FOR Q3 2021 ON OMAVELOXOLONE FOR PATIENTS WITH FA AND REATA ANNOUNCES PLAN TO FILE OMAVELOXOLONE NDA DURING Q1 2022
PROVIDES UPDATE FROM MID-CYCLE COMMUNICATION MEETING ON BARDOXOLONE FOR PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME
PROVIDES UPDATE FROM TYPE B MEETING ON BARDOXOLONE FOR PATIENTS WITH ADPKD
ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 MERLIN TRIAL OF BARDOXOLONE IN PATIENTS WITH CKD AT RISK OF RAPID PROGRESSION
REAFFIRMS CASH RUNWAY THROUGH MID-2024
CONFERENCE CALL WITH MANAGEMENT ON AUGUST 9, 2021 AT 4:30 P.M. ET
... More
